New Concerns Dog the FDA

The interim appointee to run the FDA has no regulatory experience and is being asked to hold two possibly conflicting positions at once

You might think that after Michael Brown's FEMA fiasco, the White House would try to avoid any appearance of cronyism in job appointments requiring technical expertise. You might think that after the Plan B contraceptive flap and safety problems with drugs like Vioxx, it would seek to avoid controversy while picking someone to run the embattled Food and Drug Administration (FDA). Think again.

The Administration moved swiftly to name Dr. Andrew von Eschenbach as interim FDA chief after the September departure of Commissioner Lester Crawford just two months after his confirmation. (The Senate is investigating a possible failure to disclose financial interests.)...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!